Literature DB >> 15908096

Apoptotic mechanisms in the pathophysiology of schizophrenia.

L Fredrik Jarskog1, Leisa A Glantz, John H Gilmore, Jeffrey A Lieberman.   

Abstract

While schizophrenia is generally considered a neurodevelopmental disorder, evidence for progressive clinical deterioration and subtle neurostructural changes following the onset of psychosis has led to the hypothesis that apoptosis may contribute to the pathophysiology of schizophrenia. Apoptosis (a.k.a. programmed cell death) is a mechanism of cell death that operates in normal neurodevelopment and is increasingly recognized for its role in diverse neuropathological conditions. Activation of apoptosis can lead to rapid and complete elimination of neurons and glia in the central nervous system. Studies also show that in certain settings, pro-apoptotic triggers can lead to non-lethal and localized apoptotic activity that produces neuritic and synaptic loss without causing cell death. Given that the neuropathology of schizophrenia is subtle and includes reduced neuropil (especially synaptic elements), limited and often layer-specific reductions of neurons, as well as neuroimaging data suggesting progressive loss of cortical gray matter in first-episode psychosis, a role for apoptosis in schizophrenia appears plausible. Studies that have examined markers of apoptosis and levels of apoptotic regulatory proteins in postmortem schizophrenia brain tissue will be reviewed in context of this hypothesis. Overall, the data seem to indicate a dysregulation of apoptosis in several cortical regions in schizophrenia, including evidence that the apoptotic vulnerability is increased. Although the exact role of apoptosis in schizophrenia remains uncertain, the potential involvement of non-lethal localized apoptosis is intriguing, especially in earlier stages of the illness.

Entities:  

Mesh:

Year:  2005        PMID: 15908096     DOI: 10.1016/j.pnpbp.2005.03.010

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  61 in total

Review 1.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

2.  Assessment of Apoptosis Pathway in Peripheral Blood of Autistic Patients.

Authors:  Mohammad Mahdi Eftekharian; Alireza Komaki; Vahid Kholghi Oskooie; Amir Namvar; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2019-07-30       Impact factor: 3.444

3.  Alternative complement pathway in schizophrenia.

Authors:  Anna Boyajyan; Aren Khoyetsyan; Andranik Chavushyan
Journal:  Neurochem Res       Date:  2010-01-26       Impact factor: 3.996

Review 4.  Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology.

Authors:  Alex Fornito; Murat Yücel; Brian Dean; Stephen J Wood; Christos Pantelis
Journal:  Schizophr Bull       Date:  2008-04-23       Impact factor: 9.306

5.  Detection of adeno-associated virus 2 and parvovirus B19 in the human dorsolateral prefrontal cortex.

Authors:  Jacqueline A Hobbs
Journal:  J Neurovirol       Date:  2006-06       Impact factor: 2.643

6.  Interaction between interleukin 3 and dystrobrevin-binding protein 1 in schizophrenia.

Authors:  Todd L Edwards; Xu Wang; Qi Chen; Brandon Wormly; Brien Riley; F Anthony O'Neill; Dermot Walsh; Marylyn D Ritchie; Kenneth S Kendler; Xiangning Chen
Journal:  Schizophr Res       Date:  2008-09-18       Impact factor: 4.939

7.  Hemispheric comparisons of neuron density in the planum temporale of schizophrenia and nonpsychiatric brains.

Authors:  John F Smiley; Gorazd Rosoklija; Branislav Mancevski; Denise Pergolizzi; Khadija Figarsky; Cynthia Bleiwas; Aleksej Duma; J John Mann; Daniel C Javitt; Andrew J Dwork
Journal:  Psychiatry Res       Date:  2011-03-05       Impact factor: 3.222

Review 8.  Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.

Authors:  Jun Ku Chung; Shinichiro Nakajima; Eric Plitman; Yusuke Iwata; Danielle Uy; Philip Gerretsen; Fernando Caravaggio; M Mallar Chakravarty; Ariel Graff-Guerrero
Journal:  Am J Geriatr Psychiatry       Date:  2016-04-29       Impact factor: 4.105

9.  Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia.

Authors:  Rosaria Di Lorenzo; Alice Brogli
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

10.  Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia.

Authors:  B K Y Bitanihirwe; M P Lim; J F Kelley; T Kaneko; T U W Woo
Journal:  BMC Psychiatry       Date:  2009-11-16       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.